(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial ...

PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the ...

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic ...

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-‘749) and its long-term systemic ...

FDA Approves Long-Acting Olanzapine Injection The FDA has approved olanzapine extended-release intramuscular injection for the treatment of schizophrenia in adults. Medscape Medical News, December 15, ...

Olanzapine showed superiority vs prochlorperazine for changes in maximum nausea score and quality of life, but not for average nausea. (HealthDay News) — Olanzapine may be better than prochlorperazine ...